Sugi Predict

Sugi Predict / Compounds / SCHEMBL968326

SCHEMBL968326

SCHEMBL968326

NS(=O)(=O)c1ccc2c(c1)CCO2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 4/20 0.57
▸ MAPT P10636 1/20 0.55
▸ CA2 P00918 6/20 0.53
▸ CA12 O43570 5/20 0.53
▸ CA1 P00915 5/20 0.53
▸ CA7 P43166 2/20 0.53
▸ CA14 Q9ULX7 2/20 0.53
▸ PKLR P30613 1/20 0.52
▸ PTGS1 P23219 2/20 0.51
▸ PTGS2 P35354 2/20 0.51
▸ PRKCI P41743 1/20 0.49
▸ PTGES2 Q9H7Z7 1/20 0.47
▸ CA9 Q16790 3/20 0.46
▸ ADRA2A P08913 1/20 0.46
▸ PNMT P11086 1/20 0.46
▸ ADRA2B P18089 1/20 0.46
▸ ADRA2C P18825 1/20 0.46
▸ KEAP1 Q14145 1/20 0.46
▸ NFE2L2 Q16236 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6674134 0.90 CA2 (0.59) PKMMAPTCA2CA12CA1
SCHEMBL7950169 0.86 CA2 (0.53) PKMMAPTCA2CA12CA1
SCHEMBL2633941 0.82 PKM (0.57) PKMMAPTCA2CA12CA1
SCHEMBL8164691 0.82 PKM (0.57) PKMMAPTPKLRPTGS1PTGS2
SCHEMBL692531 0.82 PKM (0.58) PKMMAPTPKLRPTGS1PTGS2
Hydrochloric Acid SCHEMBL27732232 0.81 PKM (0.56) PKMMAPTCA2CA12CA1
Glycine SCHEMBL2316017 0.80 KEAP1 (0.55) PKMMAPTCA2CA12CA1
SCHEMBL2549992 0.79 PKM (0.61) PKMCA2CA12PKLRPTGS1
SCHEMBL14457118 0.79 PKM (0.55) PKMMAPTCA2CA12CA1
SCHEMBL29156174 0.78 PKM (0.54) PKMMAPTPKLRPRKCIKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022096-A1 NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS GENECODE (EE) 2026-01-22 — — US claimed
CN-108884093-A 6,7,8,9- tetrahydro -5H- pyrido [2,3-d] azepine * dopamine D 3 ligands 辉瑞公司 2018-11-23 — — CN claimed
US-20090270383-A1 Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias ASTRAZENECA AB (SE) 2009-10-29 — — US claimed
EP-0583960-B1 Synthesis of bicyclic aromatic sulfonic acids, sulfonyl chlorides and sulfonamides LILLY CO ELI (US) 1997-05-21 — — EP claimed
US-5387681-A Reacting a bicyclic aromatic compound with a complex of sulfur trioxide-N,N-dimethylformamide; water miscible, non-reactive solvent; thionyl halide ELI LILLY AND COMPANY (US) 1995-02-07 — — US claimed
EP-0583960-A2 Synthesis of bicyclic aromatic sulfonic acids, sulfonyl chlorides and sulfonamides ELI LILLY AND COMPANY (US) 1994-02-23 — — EP claimed
US-20260022096-A1 NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS GENECODE (EE) 2026-01-22 — — US disclosed
CN-118852135-A N-acyl sulfonamide compound, preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2024-10-29 — — CN disclosed
US-20240228463-A1 SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME GENENTECH, INC. (US) 2024-07-11 — — US disclosed
CN-113773242-B Indol-2-one BRD4 inhibitor and preparation and application thereof 兰州大学 2023-10-27 — — CN disclosed
US-20230104936-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-04-06 — — US disclosed
US-20230082167-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC (US) 2023-03-16 — — US disclosed
WO-2023028077-A1 SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME GENENTECH, INC. (US) 2023-03-02 — — WO disclosed
EP-0222475-A1 Sulfonyl ureas with anti-tumour activity ELI LILLY AND COMPANY (US) 1987-05-20 — — EP disclosed
US-4659709-A LESS ADVERSE SIDE-EFFECTS SHIONOGI & CO. (JP) 1987-04-21 — — US disclosed
US-4659709-A LESS ADVERSE SIDE-EFFECTS SHIONOGI & CO. (JP) 1987-04-21 — — US disclosed
US-4659709-A LESS ADVERSE SIDE-EFFECTS SHIONOGI & CO. (JP) 1987-04-21 — — US disclosed
EP-0173899-A2 2,3-Dihydrobenzofuran-5-sulfonamide derivatives SHIONOGI & CO., LTD. (JP) 1986-03-12 — — EP disclosed
EP-0173899-A2 2,3-Dihydrobenzofuran-5-sulfonamide derivatives SHIONOGI & CO., LTD. (JP) 1986-03-12 — — EP disclosed
EP-0173899-A2 2,3-Dihydrobenzofuran-5-sulfonamide derivatives SHIONOGI & CO., LTD. (JP) 1986-03-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270383-A1 Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias KCNH1, RYR1, CACNA1E PKM 3630/4885MAPT 4599/4885CA2 2459/4885
US-20260022096-A1 NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS CNR1, CDR2, SMN1; SMN2 PKM 3314/4885MAPT 2123/4885CA2 240/4885
US-20240228463-A1 SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME CACNA1I, CACNA1B, CACNA1C PKM 3806/4885MAPT 3123/4885CA2 95/4885
US-20230104936-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 PKM 527/4885MAPT 1167/4885CA2 294/4885
US-20230082167-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 PKM 956/4885MAPT 3096/4885CA2 1885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.